About the Event

Places are strictly limited. Participation in the program is subject to written approval and confirmation by BioMelbourne Network.

Please submit your expression of interest below.

Transitioning from the discovery phase to approved pharmaceutical product represents a pivotal and challenging journey for biotech and pharma companies. To support Australian companies navigating this crucial transition and wishing to enter the European market, Serum Life Science Europe GmbH (SLS Europe) is offering a tailored Masterclass designed to address the unique challenges and opportunities that arise during this phase.

With a comprehensive understanding of the entire product development spectrum, SLS Europe serves a diverse range of organisations, from small start-ups to large enterprises, private funding bodies, and academic research groups. Leveraging its expertise as a German-based regulatory consultancy and robust global network, SLS Europe aims to provide participants with the knowledge and strategies necessary for successful clinical development and European regulatory approval.

About the Masterclass

The Masterclass Program is specifically designed to assist companies at a critical phase in their development process. Moving beyond initial discovery, the focus is on the rigorous demands of clinical development, regulatory approvals and strategic market entry into Europe.

The Masterclass will build on foundational knowledge while introducing concepts and practical strategies tailored to the clinical stage.

Participants will receive a clear roadmap and actionable strategies to navigate the clinical journey towards successful European market integration.

Be informed about:

• Regulatory guidance
• Clinical development strategy
• Market entry planning.

What to expect:

• The latest updates from industry experts
• Engaging information for diverse audiences
• Dynamic panel Q&A session
• In-person networking opportunities with peers.

Who should attend?

• Biopharma professionals seeking to improve knowledge, skills and expertise.
• Biotech and pharma companies transitioning from discovery to clinical stages
• Early-stage companies (late pre-clinical / clinical stage) with ambitions to develop products for the local or global market
• Founders, CEOs, CSOs, CTOs, commercial heads, BD managers, researchers, scientists.

Places are strictly limited. Participation in the program is subject to written approval and confirmation by BioMelbourne Network.

Program details

This Masterclass program has three parts:

• Part A | BioForum: Tuesday 18 June 2024 | afternoon event, 1.5 hours, plus 1 hour networking
• Part B | Masterclass Workshop: Wednesday 19 June 2024 | 9:00 am – 5:00 pm
• Part C | 30-minute Advisory Session: Thursday 20 June – Friday 21 June 2024 (Individual meeting times to be advised)

Registration for the program includes:

• Two additional complimentary registrations for colleagues to attend the BioForum
• Attendance at the full-day Masterclass workshop for one company representative
• One 30-minute advisory session (two company representatives may attend).

Submit an EOI.

---